In conclusion, hereditary genetic polymorphisms and the expression levels of EGF and VEGF can serve as prognostic predictors of patients with advanced ESCC, and provide insight for optimizing personalized therapy for patients with ESCC. The gene discussed is EGF; the disease is esophageal squamous cell carcinoma.